ArticleTranslational vision science & technology2025
Clinical and Clustering-Based Subtyping of Extensive Macular Atrophy With Pseudodrusen-Like Appearance (EMAP).
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the usefulness of hierarchical clustering to classify extensive macular atrophy with pseudodrusen-like appearance (EMAP) based on macular and peripheral atrophy extension. Methods: In this cross-sectional study, all participants underwent best-corrected visual acuity (BCVA) testing, optical coherence tomography (OCT), short-wavelength fundus autofluorescence (SW-AF), and ultra-widefield color fundus photography (UWF-CFP). Peripheral atrophy was quantified in degrees using OptosAdvance software, and macular atrophy area was manually measured. Based on the relative proportion of macular and peripheral atrophy, eyes were clinically classified as having predominantly central, mixed, or predominantly peripheral disease. Hierarchical clustering was performed using macular atrophy area and peripheral angular extension. Results: Eighty-five eyes from 45 EMAP patients (mean age, 64.0 ± 8.7 years; 26 females, 57.8%) were included. Peripheral pavingstone-like degeneration was observed in 57% of eyes. Four clusters were identified: Cluster 1, minimally atrophic (20%); Cluster 2, predominantly central (20%); Cluster 3, mixed (27%); and Cluster 4, predominantly peripheral (33%). Cluster 2 showed significantly worse BCVA (P = 0.013 vs. Cluster 1; P = 0.007 vs. Cluster 4) and higher prevalence of foveal atrophy (P = 0.004) and fibrosis (P < 0.0001). No significant differences in age or refractive error were found among the groups. Conclusions: Clinical and clustering-based classifications converged on consistent EMAP subtypes defined by macular and peripheral atrophy distribution. These findings suggest that combining clinical expertise with data-driven methods can help describe disease variability and guide future research. Translational Relevance: Integrating clinical expertise with unsupervised clustering may improve the identification of EMAP subtypes, aiding patient selection and outcome stratification in future trials and longitudinal studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.